Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Master's Award: Canada Graduate Scholarships

University of Toronto

$17,500.00

Investigating LOXL2 as a Therapeutic Target to Overcome Radioresistance in Prostate Cancer

EF 2021-22

Résumé
Prostate cancer (PCa) is the most commonly diagnosed cancer in male Canadians, yet resistance to radiation treatment leading to metastatic progression is still a cause of significant morbidity and mortality in patients. A recent study of our radioresistant PCa cell line DU-145 found a significant increase of lysyl oxidase-like 2 (LOXL2), an extracellular matrix (ECM) cross-linking enzyme. LOXL2 has previously been associated with radioresistance, as well as promoting metastasis and fibrosis through ECM remodelling. Aptly, two LOXL2 inhibitors have already passed phase I clinical trials for fibrotic disease. I hypothesize that increased LOXL2 promotes radioresistance and metastasis in PCa cells, and its pharmacological inhibition can be used therapeutically to target these processes.My first aim will be to confirm that targeting LOXL2 sensitizes PCa cells to radiation. I will perform clonogenic assays with radioresistant DU-145 cells to determine whether genetically or pharmacologically inhibiting LOXL2 sensitizes these cells to radiation. I will also perform these assays on clinically-relevant patient-derived cells. My second aim evaluates the metastatic potential of DU-145 PCa cells using the CAM assay, which measures the extent to which metastatic cells injected into the blood vessel of a chick egg chorioallantoic membrane (CAM) can exit the vessel to invade nearby tissue. The third aim of my project will use a preclinical mouse model injected with DU-145 cells to evaluate the therapeutic efficacy of the clinically approved LOXL2 inhibitors in sensitizing PCa cells to radiation.The proposed research will elucidate the mechanisms of LOXL2 radioresistance and metastasis, while paving the way for the use of approved LOXL2 inhibitors to treat PCa in clinical trials.
Programme
Master's Award: Canada Graduate Scholarships
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
466690
Name
Frame Gavin C
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Investigating LOXL2 as a Therapeutic Target to Overcome Radioresistance in Prostate Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of Toronto
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Clonogenic Assay; Invasion Assay; Loxl2; Metastatic; Mouse Model; Patient-Derived Cells; Pharmacological Inhibitors; Preclinical; Prostate Cancer; Tumour Xenograft
Abstract
Prostate cancer (PCa) is the most commonly diagnosed cancer in male Canadians, yet resistance to radiation treatment leading to metastatic progression is still a cause of significant morbidity and mortality in patients. A recent study of our radioresistant PCa cell line DU-145 found a significant increase of lysyl oxidase-like 2 (LOXL2), an extracellular matrix (ECM) cross-linking enzyme. LOXL2 has previously been associated with radioresistance, as well as promoting metastasis and fibrosis through ECM remodelling. Aptly, two LOXL2 inhibitors have already passed phase I clinical trials for fibrotic disease. I hypothesize that increased LOXL2 promotes radioresistance and metastasis in PCa cells, and its pharmacological inhibition can be used therapeutically to target these processes.My first aim will be to confirm that targeting LOXL2 sensitizes PCa cells to radiation. I will perform clonogenic assays with radioresistant DU-145 cells to determine whether genetically or pharmacologically inhibiting LOXL2 sensitizes these cells to radiation. I will also perform these assays on clinically-relevant patient-derived cells. My second aim evaluates the metastatic potential of DU-145 PCa cells using the CAM assay, which measures the extent to which metastatic cells injected into the blood vessel of a chick egg chorioallantoic membrane (CAM) can exit the vessel to invade nearby tissue. The third aim of my project will use a preclinical mouse model injected with DU-145 cells to evaluate the therapeutic efficacy of the clinically approved LOXL2 inhibitors in sensitizing PCa cells to radiation.The proposed research will elucidate the mechanisms of LOXL2 radioresistance and metastasis, while paving the way for the use of approved LOXL2 inhibitors to treat PCa in clinical trials.
Competitiondate
202112
Approvedterm2
1 yr 0 mth
Pinamesdelim
Frame, Gavin C
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~